BDRL Statistics
Total Valuation
Blonder Tongue Laboratories has a market cap or net worth of 900,431.
| Market Cap | 900,431 |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Wednesday, March 26, 2025.
| Earnings Date | Mar 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Blonder Tongue Laboratories has 14.52 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 14.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.05 |
| PB Ratio | 0.77 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 10.06.
| Current Ratio | 0.98 |
| Quick Ratio | 0.43 |
| Debt / Equity | 10.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.55 |
| Interest Coverage | -2.70 |
Financial Efficiency
Return on equity (ROE) is -133.98% and return on invested capital (ROIC) is -12.67%.
| Return on Equity (ROE) | -133.98% |
| Return on Assets (ROA) | -9.90% |
| Return on Capital (ROIC) | -12.67% |
| Revenue Per Employee | 270,373 |
| Profits Per Employee | -43,582 |
| Employee Count | 67 |
| Asset Turnover | 1.35 |
| Inventory Turnover | 2.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.00% in the last 52 weeks. The beta is 0.68, so Blonder Tongue Laboratories's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 46.40 |
| Average Volume (20 Days) | 11,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Blonder Tongue Laboratories had revenue of 18.12 million and -2.92 million in losses. Loss per share was -0.22.
| Revenue | 18.12M |
| Gross Profit | 5.46M |
| Operating Income | -2.13M |
| Pretax Income | -2.92M |
| Net Income | -2.92M |
| EBITDA | -2.01M |
| EBIT | -2.13M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 79,000 in cash and 10.80 million in debt, giving a net cash position of -10.72 million or -0.74 per share.
| Cash & Cash Equivalents | 79,000 |
| Total Debt | 10.80M |
| Net Cash | -10.72M |
| Net Cash Per Share | -0.74 |
| Equity (Book Value) | 1.07M |
| Book Value Per Share | 0.08 |
| Working Capital | -188,000 |
Cash Flow
In the last 12 months, operating cash flow was -1.38 million and capital expenditures -48,000, giving a free cash flow of -1.43 million.
| Operating Cash Flow | -1.38M |
| Capital Expenditures | -48,000 |
| Free Cash Flow | -1.43M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 30.16%, with operating and profit margins of -11.76% and -16.12%.
| Gross Margin | 30.16% |
| Operating Margin | -11.76% |
| Pretax Margin | -16.12% |
| Profit Margin | -16.12% |
| EBITDA Margin | -11.07% |
| EBIT Margin | -11.76% |
| FCF Margin | n/a |
Dividends & Yields
Blonder Tongue Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.30% |
| Shareholder Yield | -9.30% |
| Earnings Yield | -324.29% |
| FCF Yield | -158.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Blonder Tongue Laboratories has an Altman Z-Score of -1.91. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.91 |
| Piotroski F-Score | n/a |